Abstract
Eculizumab is a humanized monoclonal antibody which binds with high affinity to the fifth component of complement preventing its cleavage into C5a and C5b. Given that the clinical manifestations of paroxysmal nocturnal haemoglobinuria (PNH) are based on the activity of C5b-9, (the membrane attack complex) on unprotected PNH erythrocytes, eculizumab was tested as a therapeutic in this disease in four clinical trials beginning in 2002, including a placebo-controlled double-blind study, and was found to have efficacy in reducing markers of intravascular haemolysis, improving haemoglobin levels and reducing transfusion requirements as well as improving renal impairment, decreasing the rate and risk of thromboembolic phenomena and improving many measurable quality of life parameters. Additionally, studies undertaken following the completion of the trials suggest an improvement in overall survival such that patients treated with eculizumab for up to 8 years appear to have survival very similar to an age- and sex-matched population. This well-tolerated therapy has maintained all of the clinical benefits seen in the clinical trials over long-term use.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Tesser JKA, Fleischmann R, Mojcik C, Bombara M, Burch F (2001) Safety and efficacy of the humanized anti-C5 antibody h5G1.1 in patients with rheumatoid arthritis. Arthritis Rheum 44:S274
Kaplan M (2002) Eculizumab (Alexion). Curr Opin Investig Drugs 3:1017–1023
Hillmen P, Hall C, Marsh JC, Elebute M, Bombara MP, Petro BE, Cullen MJ, Richards SJ, Rollins SA, Mojcik CF, Rother RP (2004) Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med 350:552–559
Hillmen P, Young NS, Schubert J, Brodsky RA, Socié G, Muus P, Röth A, Szer J, Elebute MO, Nakamura R, Browne P, Risitano AM, Hill A, Schrezenmeier H, Fu CL, Maciejewski J, Rollins SA, Mojcik CF, Rother RP, Luzzatto L (2006) The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med 355:1233–1243
Brodsky RA, Young NS, Antonioli E, Risitano AM, Schrezenmeier H, Schubert J, Gaya A, Coyle L, de Castro C, Fu CL, Maciejewski JP, Bessler M, Kroon HA, Rother RP, Hillmen P (2008) Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Blood 111:1840–1847
Kanakura Y, Ohyashiki K, Shichishima T, Okamoto S, Ando K, Ninomiya H, Kawaguchi T, Nakao S, Nakakuma H, Nishimura J, Kinoshita T, Bedrosian CL, Valentine ME, Khursigara G, Ozawa K, Omine M (2011) Safety and efficacy of the terminal complement inhibitor eculizumab in Japanese patients with paroxysmal nocturnal hemoglobinuria: the AEGIS clinical trial. Int J Hematol 93:36–46
Nishimura J, Yamamoto M, Hayashi S, Ohyashiki K, Ando K, Brodsky AL, Noji H, Kitamura K, Eto T, Takahashi T, Masuko M, Matsumoto T, Wano Y, Shichishima T, Shibayama H, Hase M, Li L, Johnson K, Lazarowski A, Tamburini P, Inazawa J, Kinoshita T, Kanakura Y (2014) Genetic variants in C5 and poor response to eculizumab. N Engl J Med 370:632–639
Hillmen P, Muus P, Röth A, Elebute MO, Risitano AM, Schrezenmeier H, Szer J, Browne P, Maciejewski JP, Schubert J, Urbano-Ispizua A, de Castro C, Socié G, Brodsky RA (2013) Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol 162:62–73
Lee JW, Jang JH, Kim JS, Yoon SS, Lee JH, Kim YK, Jo DY, Chung J, Sohn SK (2013) Clinical signs and symptoms associated with increased risk for thrombosis in patients with paroxysmal nocturnal hemoglobinuria from a Korean Registry. Int J Hematol 97:749–757
Kanakura Y, Ohyashiki K, Shichishima T, Okamoto S, Ando KH, Kawaguchi T, Nakao S, Nakakuma H, Nishimura J, Kinoshita T, Bedrosian CL, Ozawa K, Omine M (2013) Long-term efficacy and safety of eculizumab in Japanese patients with PNH: AEGIS trial. Int J Hematol 98:406–416
Ueda T, Hayakawa J, Yamanishi M, Maeda M, Fukunaga Y (2013) Efficacy of eculizumab in a patient with paroxysmal nocturnal hemoglobinuria requiring transfusions 14 years after a diagnosis in childhood. J Nippon Med Sch 80:155–159
Kurita N, Obara N, Fukuda K, Nishikii H, Sato S, Inagawa S, Kurokawa T, Owada Y, Ninomiya H, Chiba S (2013) Perisurgical induction of eculizumab in a patient with paroxysmal nocturnal hemoglobinuria: its inhibition of surgery-triggered hemolysis and the consequence of subsequent discontinuation. Blood Coagul Fibrinolysis 24:658–662
Kelly RJ, Höchsmann B, Szer J, Kulasekararaj A, de Guibert S, Röth A, Weitz IC, Armstrong E, Risitano AM, Patriquin CJ, Terriou L, Muus P, Hill A, Turner MP, Schrezenmeier H, Peffault de Latour R (2015) Eculizumab in pregnant patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med 373:1032–1039
Parker C (2009) Eculizumab for paroxysmal nocturnal haemoglobinuria. Lancet 373:759–767
Hill A, Richards SJ, Rother RP, Hillmen P (2007) Erythopoietin treatment during complement inhibition with eculizumab in a patient with paroxysmal nocturnal hemoglobinuria. Haematologica 92:e31–e33
Gurion R, Gafter-Gvili A, Paul M, Vidal L, Ben-Bassat I, Yeshurun M, Shpilberg O, Raanani P (2009) Hematopoietic growth factors in aplastic anemia patients treated with immunosuppressive therapy-systematic review and meta-analysis. Haematologica 94:712–719
Hill A, Kelly RJ, Hillmen P (2013) Thrombosis in paroxysmal nocturnal hemoglobinuria. Blood 121:4985–4996
Hall C, Richards S, Hillmen P (2003) Primary prophylaxis with warfarin prevents thrombosis in paroxysmal nocturnal haemoglobinuria. Blood 102:3587–3591
van Bijnen ST, van Rijn RS, Koljenovic S, Te Boekhorst P, Muus P (2012) Possible high risk of thrombotic events in patients with paroxysmal nocturnal haemoglobinuria after discontinuation of eculizumab. Br J Haematol 157:762–763
Cella D (1997) Manual of the functional assessment of chronic illness therapy (FACIT) measurement system. Version 4. Center on Outcomes Research and Education (CORE), Evanston Northwestern Healthcare and Northwestern University, Evanston
Fayers PM, Aaronson NK, Bjordal K, Groenvold M, Curran D, on behalf of the EORTC Quality of Life Study Group (2001) The EORTC QLQ-C30 scoring manual, 3rd edn. European Organisation for Research and Treatment of Cancer, Brussels
MartÃ-Carvajal AJ, Anand V, Cardona AF, Solà I (2014) Eculizumab for treating patients with paroxysmal nocturnal hemoglobinuria. Cochrane Database Syst Rev 10:CD010340
Hill A, Rother RP, Hillmen P (2005) Improvement in the symptoms of smooth muscle dystonia during eculizumab therapy in paroxysmal nocturnal hemoglobinuria. Haematologica 90:e111–e113
Grigg A, Brown M, Szer J (2010) Durable resolution of recurrent microvascular small bowel ischaemia and severe abdominal pain by eculizumab in paroxysmal nocturnal haemoglobinuria. Intern Med J 40:794–795
Hillmen P, Elebute M, Kelly R, Urbano-Ispizua A, Hill A, Rother RP, Khursigara G, Fu CL, Omine M, Browne P, Rosse W (2010) Long-term effect of the complement inhibitor eculizumab on kidney function in patients with paroxysmal nocturnal hemoglobinuria. Am J Hematol 85:553–559
Hill A, Sapsford RJ, Scally A, Kelly R, Richards SJ, Khurisgara G, Sivananthan MU, Hillmen P (2012) Under-recognised complications in patients with paroxysmal nocturnal haemoglobinuria: raised pulmonary pressure and reduced right ventricular function. Br J Haematol 158:409–414
Hill A, Rother RP, Wang X, Morris SM Jr, Quinn-Senger K, Kelly R, Richards SJ, Bessler M, Bell L, Hillmen P, Gladwin MT (2010) Effect of eculizumab on haemolysis-associated nitric oxide depletion, dyspnoea, and measures of pulmonary hypertension in patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol 149:414–425
Hillmen P, Lewis SM, Bessler M, Luzzatto L, Dacie JV (1995) Natural history of paroxysmal nocturnal hemoglobinuria. N Engl J Med 333:1253–1258
Loschi M, Porcher R, Barraco F, Terriou L, Mohty M, de Guibert S, Mahe B, Lemal R, Dumas PY, Etienne G, Jardin F, Royer B, Bordessoule D, Rohrlich PS, Fornecker LM, Salanoubat C, Maury S, Cahn JY, Vincent L, Sene T, Rigaudeau S, Nguyen S, Lepretre AC, Mary JY, Corront B, Socie G, Peffault de Latour R (2016) Impact of eculizumab treatment on paroxysmal nocturnal hemoglobinuria: a treatment versus no-treatment study. Am J Hematol 91:366–370
Kelly RJ, Hill A, Arnold LM, Brooksbank GL, Richards SJ, Cullen M, Mitchell LD, Cohen DR, Gregory WM, Hillmen P (2011) Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival. Blood 117:6786–6792
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer Japan KK
About this chapter
Cite this chapter
Szer, J. (2017). Clinical Effects of Eculizumab in PNH. In: Kanakura, Y., Kinoshita, T., Nishimura, Ji. (eds) Paroxysmal Nocturnal Hemoglobinuria. Springer, Tokyo. https://doi.org/10.1007/978-4-431-56003-6_16
Download citation
DOI: https://doi.org/10.1007/978-4-431-56003-6_16
Published:
Publisher Name: Springer, Tokyo
Print ISBN: 978-4-431-56001-2
Online ISBN: 978-4-431-56003-6
eBook Packages: MedicineMedicine (R0)